View Older Stories View More Recent Stories

Aug 15, 2022 08:00AM Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases
Aug 15, 2022 08:00AM Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases
Aug 3, 2022 07:00AM Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjusted EBITDA Guidance
Jul 25, 2022 08:02AM Horizon Therapeutics plc Named a Best Company for Multicultural Women
Jul 21, 2022 08:00AM Horizon Therapeutics plc Announces Inaugural #RAREis Global Advocate Grant Recipients
Jul 11, 2022 08:00AM Horizon Therapeutics plc Announces Wanda Durant Has Joined Olympian Gail Devers to Raise Awareness of Thyroid Eye Disease Among Graves’ Disease Community
Jul 8, 2022 08:01AM Horizon Therapeutics (HZNP) Announces FDA Approval of KRYSTEXXA Injection Co-Administered With Methotrexate
Jul 8, 2022 08:00AM FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy
Jul 7, 2022 08:00AM Horizon Therapeutics plc to Release Second-Quarter 2022 Financial Results and Host Webcast on Aug. 3, 2022
Jun 24, 2022 12:34PM Horizon Therapeutics (HZNP) Announces New Analysis Finds UPLIZNA Effective Among European Populations with NMOSD
Jun 24, 2022 12:30PM New Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Jun 15, 2022 08:33AM Horizon Therapeutics (HZNP) Submits Regulatory Filing for UPLIZNA in Brazil
Jun 15, 2022 08:30AM Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA® (inebilizumab) in Brazil
Jun 15, 2022 07:45AM Horizon Therapeutics plc Named One of the Fortune Best Workplaces in Chicago™
Jun 11, 2022 10:00AM Analysis of Pooled Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials Reinforces Safety Profile in People with Thyroid Eye Disease (TED)
Jun 9, 2022 08:00AM Horizon Therapeutics plc Named a Top Company for Executive Women
Jun 6, 2022 04:30PM Horizon Therapeutics plc to Present at the Goldman Sachs 43rd Annual Global Health Care Conference
Jun 2, 2022 08:00AM Horizon Therapeutics plc to Highlight Data and Education on Thyroid Eye Disease (TED) at the Endocrine Society (ENDO) 2022 Annual Conference
Jun 1, 2022 08:02AM Horizon Therapeutics (HZNP) Reports Data from MIRROR Trial Showing KRYSTEXXA Plus Methotrexate Resulted in Significant Improvement in Efficacy and Safety
Jun 1, 2022 08:00AM Data Presented from the MIRROR Randomized Controlled Trial Demonstrate KRYSTEXXA® (pegloticase injection) Plus Methotrexate Resulted in Significant Improvement in Efficacy and Safety (Infusion Reacti
May 31, 2022 04:01PM Horizon Therapeutics plc Wins 2022 International CSR Excellence Award for #RAREis Adoption Fund
May 31, 2022 08:00AM Analysis from the Phase 3 N-MOmentum Study Demonstrates the Effectiveness of UPLIZNA® (inebilizumab-cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations
May 24, 2022 08:00AM Horizon Therapeutics plc to Present MIRROR Randomized Controlled Trial Primary Endpoint Data at The EULAR 2022 European Congress of Rheumatology
May 17, 2022 08:00AM Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata
May 16, 2022 09:00AM Horizon Therapeutics plc Ranked Second in Overall Corporate Reputation in U.S. PatientView Survey of Patient Groups
May 11, 2022 09:02AM Horizon Therapeutics plc Announces Dara Mann as a Healthcare Businesswomen’s Association 2022 Rising Star
May 11, 2022 08:30AM Horizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head On
May 9, 2022 04:44PM Horizon Therapeutics and Chicago Sky Announce Multi-Year Partnership
May 4, 2022 07:00AM Horizon Therapeutics plc Reports First-Quarter 2022 Financial Results
May 3, 2022 09:15AM Horizon Therapeutics (HZNP) Announces Phase 2 Study of Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis
May 3, 2022 09:15AM Topline Data for Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis
May 2, 2022 04:05PM Horizon Therapeutics plc Launches #RAREis Global Advocate Grant Program to Support the Rare Disease Community
May 2, 2022 06:27AM Horizon Therapeutics (HZNP) Receives European Commission Approval of UPLIZNA for Treatment of Adults With Neuromyelitis Optica Spectrum Disorder
May 2, 2022 01:00AM Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Apr 27, 2022 08:01AM Horizon Therapeutics plc Among Top Companies for Overall Corporate Reputation in 2021 Global PatientView Survey of Patient Groups Worldwide
Apr 19, 2022 09:00AM Horizon Therapeutics and Massachusetts Institute of Technology (MIT) Solve Announce Second Annual Horizon Prize to Inspire Solutions that Improve the Quality of Life for the Global Rare Disease Commun
Apr 14, 2022 08:00AM Horizon Therapeutics plc to Release First-Quarter 2022 Financial Results and Host Webcast on May 4, 2022
Apr 11, 2022 09:20AM Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For®
Mar 31, 2022 08:35AM Horizon Therapeutics (HZNP) Reports New Data Showing UPLIZNA is Effective for People with Newly-Presenting Neuromyelitis Optica Spectrum Disorder (NMOSD)
Mar 31, 2022 08:30AM New Analysis Finds UPLIZNA® (inebilizumab-cdon) Effective for People with Newly-Presenting Neuromyelitis Optica Spectrum Disorder (NMOSD)
Mar 24, 2022 04:00AM Horizon Therapeutics plc Named as One of the Best Workplaces in Ireland
Mar 7, 2022 08:01AM Horizon Therapeutics (HZNP) Granted FDA Priority Review of sBLA for Concomitant Use of KRYSTEXXA Plus Methotrexate
Mar 7, 2022 08:00AM Horizon Therapeutics plc Announces FDA Has Granted Priority Review of the Supplemental Biologics License Application (sBLA) for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotre
Mar 2, 2022 08:00AM Horizon Therapeutics plc Partners with Christine Ha, First Blind Contestant and Winner of MasterChef, to Amplify Her Unstoppable NMOSD Story
Mar 1, 2022 07:00AM Horizon Therapeutics plc Reports Fourth-Quarter 2021 and Full-Year 2021 Financial Results; Announces Full-Year 2022 Guidance
Feb 28, 2022 09:00AM Horizon Therapeutics plc Launches #RAREis Representation Program to Elevate Global Rare Disease Equity
Feb 23, 2022 08:00AM Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)
Feb 21, 2022 04:05PM Horizon Therapeutics plc to Present at the Cowen and Company 42nd Annual Health Care Conference
Feb 16, 2022 08:15AM Horizon Therapeutics plc Names Sean Clayton Executive Vice President and General Counsel
Feb 16, 2022 08:02AM Horizon Therapeutics (HZNP) Reports New Data Demonstrating UPLIZNA Reduces Severity of Attacks Associated with Neuromyelitis Optica Spectrum Disorder (NMOSD)
View More Recent Stories View Older Stories